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Abstract
Following proviral integration into the host cell genome and establishment of a latent state,
the human immunodeficiency virus type 1 (HIV-1) can reenter a productive life cycle in
response to various stimuli. HIV-1 reactivation occurs when transcription factors, such as
nuclear factor-κB (NF-κB), nuclear factor of activated T cells (NFAT), and activator protein
-1 (AP-1), bind cognate sites within the long terminal repeat (LTR) region of the HIV-1 provi-
rus to promote transcription. Interestingly, pattern recognition receptors (PRRs) that recog-
nize pathogen-associated molecular patterns (PAMPs) can reactivate latent HIV-1 through
activation of the transcription factor NF-κB. Some PRRs are expressed on central memory
CD4+ T cells (TCM), which in HIV-1 patients constitute the main reservoir of latent HIV-1.
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), interacts with
PRRs through membrane components. However, the ability of Mtb to reactivate latent HIV-
1 has not been extensively studied. Here we show that phosphatidylinositol mannoside 6
(PIM6), a component of the Mtb membrane, in addition to whole bacteria in co-culture, can
reactivate HIV-1 in a primary TCM cell model of latency. Using a JLAT model of HIV-1
latency, we found this interaction to be mediated through Toll-like receptor-2 (TLR-2). Thus,
we describe a mechanism by which Mtb can exacerbate HIV-1 infection. We hypothesize
that chronic Mtb infection can drive HIV-1 reactivation. The phenomenon described here
could explain, in part, the poor prognosis that characterizes HIV-1/Mtb co-infection.
Introduction
Tuberculosis is the leading cause of death for individuals living with human immunodefi-
ciency virus type-1 (HIV-1) [1–4]. In 2015 alone, it was estimated that one in every three
deaths among HIV-1-infected individuals was due to TB [2]. HIV-1-infected individuals are
~20–30 times more likely to contract TB compared to uninfected individuals [5]. HIV-1/Mtb
co-infected patients exhibit accelerated HIV-1 disease and shorter overall survival [6]. In addi-
tion, the risk for active TB infection increases from around 10% in a lifetime to 10% per year
for patients that are co-infected with HIV-1 [3]. This accelerated disease progression indicates
an interaction between these two pathogens.







Citation: Larson EC, Novis CL, Martins LJ, Macedo
AB, Kimball KE, Bosque A, et al. (2017)
Mycobacterium tuberculosis reactivates latent HIV-
1 in T cells in vitro. PLoS ONE 12(9): e0185162.
https://doi.org/10.1371/journal.pone.0185162
Editor: Pere-Joan Cardona, Fundació Institut
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Mycobacterium tuberculosis (Mtb) is the causative agent of TB. HIV-1 has been proposed to
exacerbate Mtb pathogenesis via multiple mechanisms. Evidence of this interaction includes:
granuloma disorganization and reduced bacterial containment due to HIV-1 replication at
sites of Mtb infection [7]; impaired phagosomal killing of Mtb in alveolar macrophages of
HIV-1/Mtb co-infected patients [8]; HIV-1 infection decreases CD4+ and CD8+ T cell counts
within granulomas [9]; and HIV-1 alters the function and phenotype of Mtb-specific T cells
[10, 11].
Mechanisms by which Mtb interacts with HIV-1 have also been investigated. It is well
established that Mtb enhances HIV-1 production and infectivity [12–16]. Toossi and col-
leagues showed that regions of the lung involved in Mtb infection (i.e. granulomas) contain
higher levels of HIV-1 Gag p24 and increased reverse transcriptase activity when compared to
uninvolved regions [17]. Mtb-triggered inflammation causes localization of HIV-1-infected
cells to these sites of inflammation [7]. Mtb promotes HIV-1 trans-infection while suppressing
major Histocompatibility Complex Class II antigen processing by dendritic cells [18]. Differ-
ent clinical strains of Mtb differentially upregulate HIV-1 production in ex vivo peripheral
blood mononuclear cells (PBMCs) [19]. Mtb co-infection induces HIV-1 expression in a
transgenic mouse model [15]. Furthermore, mycobacterial components signaling via TLR-2
accelerate viral production in co-stimulated T cells [20]. In this work, we describe a new mech-
anism by which these two pathogens might synergize: Mtb-induced latency reversal in HIV-1
infected central memory T cells (TCM).
Microbial infections are often sensed by the innate immune system via host-expressed pat-
tern recognition receptors (PRRs) [21, 22]. PRRs recognize many classes of molecules charac-
teristic of infectious agents including nucleic acids, proteins, lipids, and carbohydrates [23].
Among PRRs, Toll-like receptor (TLRs) are present on the cell surface (TLR-1,2,4,5,6,10) or
within endosomes (TLR-3,7,8,9) that recognize such pathogen-associated molecular patterns
(PAMP) [24]. TLRs are common on immune system cells including: dendritic cells, macro-
phages, granulocytes, T cells, B cells, NK cells and mast cells [23].
Previously, Novis et al. demonstrated the ability of TLR-1/2 agonists to reactivate latent
HIV-1 in vitro [25]. The synthetic lipopeptide TLR1/2 agonist, Pam3CSK4, lead to reactivation
of latent HIV-1 in cultured TCM cells from healthy donors, and also in CD4
+ T cells from
aviremic HIV-1 patients. It was shown that the transcription factors NF-κB, NFAT and AP-1
cooperated to induce viral reactivation downstream of TLR-1/2 stimulation. Recently, the
mycobacterial membrane component, phosphatidylinositol mannoside 6 (PIM6), was shown
to accelerate HIV-1 viral production in co-stimulated CD3+ T cells through TLR-2 activation
[20]. In the present study, we describe the ability of whole Mtb (H37Ra) and Mycobacterium
smegmatis in co-culture, H37Rv lysate and PIM6, but not lipoarabinomannan (LAM; a com-
ponent of the bacterial cell wall), to reactivate latent HIV-1 in JLAT 10.6 (JLAT) cells and in a
cultured human TCM model of HIV-1 latency [25–29]. These data support the hypothesis that
Mtb, in part through TLR-2, activates pro-inflammatory pathways to enhance transcription of
latent HIV-1 during co-infection.
Results
PIM6 and H37Rv lysate activate HIV-1 reporter GFP in TLR-
2-overexpressing JLAT 10.6 cell
We tested whether Mtb could reactivate latent HIV-1 using the JLAT 10.6 clone [26]. This cell
line contains an integrated copy of HIV-1 and expresses GFP after HIV-1 reactivation from
latency. The positive control, phorbol 12-myristate 13-acetate (PMA) activates protein kinase
C to yield the expected expression of GFP (Fig 1A). In this cell line, very low responses were
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detected with the test agents (H37Ra or Mycobacterium smegmatis in co-culture, H37Rv lysate,
PIM6, and LAM). It has been observed that Jurkat cells have low levels of TLR-2 expression
and are insensitive to TLR-2 agonists [25, 30]. Therefore, in order to more efficiently test the
specific role of TLR-2 in HIV-1 reactivation we stably transduced TLR-2 with a lentiviral vec-
tor to express high levels of TLR-2 (JLAT-TLR2) (S1 Fig). PIM6 and H37Rv lysate reactivated
latent HIV-1 in the JLAT-TLR2 cells (Fig 1B). Whereas H37Ra, M. smegmatis and LAM did
not cause significant reactivation in the JLAT-TLR2 cells. To confirm that the reactivation
seen was indeed dependent on TLR-2 signaling, we tested the same conditions in the presence
of a TLR-2 neutralizing antibody (PAb-hTLR2). Incubation with the TLR-2 neutralizing anti-
body significantly attenuated induction of GFP by PIM6 and H37Rv lysate (Fig 1C). A down-
stream mediator of TLR-2 activation is the transcription factor, NF-κB. Intriguingly, the HIV-
Fig 1. PIM6 and H37Rv lysate induce GFP expression through TLR-2. A) JLAT cells were incubated for 16 hours and GFP expression was
measured by flow cytometry. Data represent mean ± SD of four independent experiments run in triplicate. *p<0.05 compared to PBS control. B)
JLAT-TLR2 cells were incubated for 16 hours and GFP expression was measured by flow cytometry. Data represent mean ± SD of ten independent
experiments run in triplicate. *p<0.05 compared to PBS control. C) JLAT-TLR2 cells were pre-incubated with the TLR-2 neutralizing antibody, PAb-
hTLR2, for 30 minutes prior to addition of test conditions. Cells were subsequently incubated for 16 hours and GFP expression was measured by
flow cytometry. Data represent mean ± SD. *p<0.05 test condition in the absence of TLR-2 neutralizing antibody compared to test condition in the
presence of TLR-2 neutralizing antibody. D) JLAT-TLR2 cells pre-incubated with BAY 11–7082 for 30 minutes prior to addition of conditions. Cells
were subsequently incubated for 16 hours and GFP expression was measured by flow cytometry. Data represent mean ± SD. *p<0.05 test condition
in the absence of BAY 11–7082 compared to test condition in the presence of BAY 11–7082.
https://doi.org/10.1371/journal.pone.0185162.g001
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1 LTR contains two NF-κB consensus binding sites within the enhancer region and NF-κB has
been shown to be necessary for HIV-1 reactivation [31]. Thus, we tested the NF-κB antagonist,
BAY 11–7082, for the ability block viral reactivation mediated by TLR-2. As expected, BAY
11–7082 attenuated viral reactivation mediated by PIM6 and H37Rv lysate (Fig 1D).
PIM6, H37Rv lysate, and whole bacteria co-culture reactivate HIV-1 in a
TCM model of latency
We sought to confirm the observations obtained with the JLAT model in a primary cell model
of latency that uses cultured TCM cells as targets for replication-competent HIV-1 [29]. For the
work presented here, a slight modification was made to the published model; we utilized a rep-
lication-competent HIV-1 construct bearing the secNLuc gene within the nef locus of HIV-
1NL4-3. Cells latently infected with this modified, replication-competent HIV-1 secrete Nano-
Luc1 luciferase enzyme into cell culture supernatant when treated with latency reversal
agents. This allows for the ability to quantify HIV-1 reactivation from the supernatant of test
cultures, providing timely detection of HIV-1 reactivation combined with the sensitivity of
luminescence. We also measured intracellular p24 Gag production by flow cytometry. By mea-
suring p24 Gag production, the results documented a statistically significant increase in re-
activation in the whole bacteria co-culture conditions (H37Ra and M. smegmatis) and H37Rv
lysate, and a trending increase PIM6 (due to inter-individual variation; Fig 2A). However,
when luciferase activity was used to measure HIV-1 reactivation in these experiments, statisti-
cally significant increases in reactivation was observed with all the tested stimuli except LAM
(Fig 2B). H37Rv lysate was observed to suppress luminescence even though latency reversal
was indicated by increased p24 Gag (S3A & S3B Fig). We tested if this observation could be
the result of H37Rv lysate interactions with the NanoLuc1 enzyme or inhibition of enzyme
secretion. Incubation of H37Rv lysate with supernatant from SupT1 cells infected with the
modified HIV-1 showed attenuated luminescence (S3C Fig). Thus, we concluded that the
observed suppression of luminescence is due to an undefined interaction with the NanoLuc1
enzyme.
Discussion
A major concern of HIV-1/Mtb co-infection in patients is accelerated HIV-1 infection [6].
While many studies provide evidence for increases in viral spread, mechanisms underlying the
impact of Mtb on latent HIV-1 reservoirs have not been investigated. In our study, we found
that whole Mycobacteria as well as their membrane component PIM6 and whole H37Rv lysate,
which is composed of a mixture of proteins, lipids and carbohydrates from the bacterial cell,
reversed HIV-1 latency. This was demonstrated using a T cell leukemia model of latency,
JLAT 10.6 T cell line, and a primary human TCM cell model of HIV-1 latency. The JLAT cell
line is a stably HIV-1-infected Jurkat cell line expresses GFP upon activation of HIV-1 LTR
transcription, and was developed by Jordan and colleagues to help enable understanding of
HIV-1 latency [26]. JLAT cells readily permit more mechanistic experiments and are ex-
tremely amenable to genetic manipulation. Thanks to this ability, we were able to generate the
TLR-2 overexpresser line used in our study. CD4+ TCM cells are thought to be an important
reservoir of latent HIV-1 in patients [32–36]. In vitro cultured TCM cells faithfully recapitulate
the biology of their in vivo counterparts and efficiently harbor latent infections [27]. The cul-
tured TCM cells reflect variations in signaling pathways found in patient populations.
Mycobacteria and some of their components were shown early on to induce HIV-1 LTR
expression in human monocytes and other cell lines [20, 37–41]. Work in 1994 by Shattock
and colleagues concluded that “phagocytosis of M. tuberculosis by monocytes expressing latent
HIV-1 latency reversal by Mycobacterium tuberculosis
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Fig 2. Reactivation of HIV by H37Ra, PIM6, and H37Rv lysate in a primary TCM model of latency. Cultured TCM cells following 72-hour
incubation with test conditions or co-stimulation with αCD3/αCD28. (A) Levels of intracellular p24 Gag were measured by flow cytometry.
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or restricted HIV-1 replication has the potential to induce or enhance viral replication in vivo”
[39]. We recently confirmed that concurrent co-infection of THP-1 macrophages by Mtb and
HIV-1 is achievable in the lab setting, but only demonstrated active replication of HIV-1in the
presence of intracellular Mtb [42]. Toossi and colleagues, in 1999, took the investigations far-
ther by showing increased production of HIV-1 transcription and viral release when HIV-1
infected monocytes from healthy donors were co-incubated with Mtb or Mtb protein compo-
nents [43]. Several groups showed this induction to be dependent on TLR-2 and to be medi-
ated, at least in part, by NF-κB binding to the HIV-1 LTR region [15, 25, 41, 43].
In addition to the mycobacteria, several other PAMP presenting organisms have been
reported to transactivate the HIV-1 LTR via TLRs 5, 7/8 or 9 [44–46]. TLR-2 can form hetero-
dimers with TLR-1 or TLR-6 to recognize many mycobacterial components including glyco-
lipids, triacylated or diacylated lipopeptides [47, 48]. TLR-2 can also cooperate with TLR-10
and Dectin-1 [49, 50]. Interestingly, HIV-1 infection of monocyte-derived macrophages and
peripheral blood mononuclear cells has been observed to up-regulate TLR-2 and TLR-4
expression [51]. This finding may indicate that HIV-1 could utilize PRRs as a self-amplifica-
tion loop for viral reactivation.
Phagocytosis of mycobacteria by macrophages results in exosome release of lipids and
other pro-inflammatory bacterial components that are capable of binding PRRs and activating
T cells [52–56]. PIM6 is an example of such a mediator. PIM6 is a powerful TLR-2 agonist
shown by Rodriguez and colleagues to up-regulate HIV-1 replication in productively infected
and CD3 co-stimulated T cells [20]. Here we report that PIM6-mediated activation of TLR-2
can also lead to HIV-1 latency reversal.
Using the intracellular p24 Gag endpoint to quantify HIV-1 reactivation in the TCM model,
we were able to show statistically significant latency reversal in cultures co-incubated with
H37Ra, M. smegmatis, and H37Rv lysate. This confirmed the basic hypothesis that the pres-
ence of Mtb in proximity to infected T cells is sufficient to reactivate latent HIV-1. While the
other stimuli, such as PIM6, showed a trend in the induction of p24 Gag production, the vari-
ability observed using latently infected primary cell culture prevented further conclusions
regarding its effects. However, when luciferase activity, a more sensitive endpoint than p24
expression, was used it became clear that, in addition to co-culture with whole Mycobacteria
and H37Rv lysate, PIM6 significantly reversed HIV-1 latency in this model. These data support
the idea that mycobacteria and mycobacterial membrane components can drive HIV-1 activa-
tion in latently infected T cells.
Experiments in JLAT cells interrogated the hypothesized major pathway of HIV-1 reactiva-
tion by Mtb. JLAT cells, while responding robustly to the positive control PMA activation, did
not show statistically significant GFP induction with any of the test conditions. However,
when TLR-2 was expressed ectopically, both PIM6 and H37Rv lysate were found to induce sig-
nificant GFP expression. We found that TLR-2 neutralizing antibody, while not affecting the
response to PMA, attenuated the induction responses of PIM6 and H37Rv lysate. Further-
more, use of the NF-κB antagonist, BAY 11–7082, also attenuated the GFP induction by PIM6
and H37Rv lysate. These data suggest that HIV-1 reactivation by PIM6 and H37Rv lysate in
The horizontal line within the box represents the median, the boundaries of the box represent the 25th- and 75th-percentile, and the whiskers
represent the maximum and minimum values. Significance for intracellular p24 Gag was determined using a 2-tailed, paired Student’s
t-test versus PBS (*p<0.05). (B) Relative luminescence was measured from supernatant of cultured TCM cells following 72-hour incubation
with conditions or co-stimulation with αCD3/αCD28. The horizontal line within the box represents the median, the boundaries of the
box represent the 25th- and 75th-percentile, and the whiskers represent the maximum and minimum values. Significance was determined
using a 2-tailed, paired Student’s t-test versus PBS (*p<0.05). Significance of individual test conditions are as follows: αCD3/αCD28
(p0.01), PIM6 (p<0.05), H37Ra (p0.01), and M. smegmatis (p0.01).
https://doi.org/10.1371/journal.pone.0185162.g002
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the TCM model occurs through activation of the TLR-2 pathway. Although whole bacteria co-
culture (H37Ra and M. smegmatis) did not significantly reactivate latent HIV-1 in the JLAT
or JLAT-TLR2 studies, they were significant in our primary TCM HIV-1 latency model. This
indicates that pathways activated in our TCM cells may vary in expression from those in the
JLATs.
Interactions between Mtb and latent HIV-1 infected cells have remained largely undefined,
yet HIV-1/Mtb co-infection is one of the world’s most lethal conditions. Our study suggests
that chronic Mtb infection could drive latency reversal in TCM cells, which may contribute to
higher viral load, increased T cell loss and thereby T cell exhaustion. Even periodic infections
by other microbial pathogens that activate TLR-2 or converging on pro-inflammatory signal-
ing pathways (e.g. NF-κB) could conceivably contribute to transiently elevated levels of vire-
mia in HIV-1 patients [25]. In poorly managed or non-compliant patients this could have
negative health outcomes [57, 58]. While our report provides the initial observation, further
work is needed to fully describe mechanisms and pathways by which mycobacteria might
affect HIV-1 latency reversal.
Materials & methods
Reagents
The following reagents were obtained through BEI Resources, NIAID, NIH: Mycobacterium
tuberculosis, Strain H37Rv, Purified Phosphatidylinositol Mannoside 6 (PIM6), NR14847;
Mycobacterium tuberculosis, Strain H37Rv, Purified Lipoarabinomannan (LAM), NR-14848;
Mycobacterium tuberculosis, Strain H37Rv, Whole Cell Lysate, NR-14822. The following bacte-
ria were obtained from ATCC: Mycobacterium tuberculosis (Zopf) Lehmann and Neumann,
Strain H37Ra, ATCC1 25177™; and Mycobacterium smegmatis (Trevisan) Lehmann and Neu-
mann, ATCC1 607™. J-Lat Full Length cells 10.6 (JLAT) (Cat. #9849), Sup-T1 cells (Cat.
#100) and nelfinavir (Cat. #4621) were obtained from the NIH AIDS Reagent Program. The
293FT cell line was obtained from Invitrogen™ (Cat. #R70007). Phorbol 12-myristate 13-ace-
tate (PMA) was obtained from Fisher BioReagents (Cat. #BP685-1).
Bacterial culture
H37Ra and M. smegmatis were grown to mid-to-late-logarithmic phase in Difco™ Middlebrook
7H9 Broth (Becton, Dickinson and Company; Cat. #271310) supplemented with ADC enrich-
ment media (Remel™, ThermoFisher Scientific, Cat. #R450592), 0.2% glycerol and 0.05%
Tween 80 at 37˚C. For assays, bacterial cultures were adjusted to a total OD600 of 1.2 reconsti-
tuted in 1 mL of phosphate buffered saline (PBS) prior to addition to wells.
Generation of stable TLR-2 expressing JLAT 10.6 cells
A bicistronic lentiviral vector derived from pFIN-EF1-GFP-2A-mCherry-WPRE (kindly pro-
vided by Dr. Susan L. Semple-Rowland, University of Florida McKnight Brain Institute) was
engineered to express TLR-2 (https://www.ncbi.nlm.nih.gov/gene/7097) in place of GFP. The
resulting lentiviral vector, pFIN-EF1-TLR2-2A-mCherry-WPRE, encodes a fusion of TLR-2
and mCherry, whose expression is driven by the elongation factor 1 (EF1) promoter (S1 Fig).
The presence of the intervening 2A peptide from porcine teschovirus-1 leads to ribosomal
skipping and equimolar production of TLR-2 and mCherry [59]. As a control, we also con-
structed a vector that only encodes the mCherry protein. J-LAT cells were infected with the
lentiviral vectors and mCherry expressing cells were isolated by FACS.
HIV-1 latency reversal by Mycobacterium tuberculosis
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JLAT and JLAT-TLR2 assays
Cell lines were maintained in RPMI1640 media supplemented 10% fetal bovine serum (FBS)
(Atlanta Biologics, Cat. #S11150) and antibiotic-antimycotic solution (100X, GIBCO, Grand
Island, NY, USA) at 37˚C, 5% CO2. JLAT and JLAT-TLR2 cells were plated at 100,000 cells/well
in 96-well U-bottom culture plates and incubated with the following conditions for 16 hours:
PBS, PMA (200 ng/mL), PIM6 (10 μg/mL), H37Rv lysate (100 μg/mL), LAM (100 μg/mL),
H37Ra (MOI 35:1) and M. smegmatis (MOI 35:1). For assays involving inhibitors, cells were pre-
incubated for 30 minutes at 37˚C in media containing PAb-hTLR2 antibody (20 μg/mL; Invivo-
Gen, Cat. Code pab-hstlr2) or BAY 11–7082 (0.30 μM; EMD Millipore Calbiochem™, Cat. #19-
687-010MG). Cells were stained for viability (BD Horizon™ Fixable Viability Stain 450) and fixed
with 1% paraformaldehyde. Viability and GFP expression was measured using a BD FACS Canto.
Primary cultured TCM cell model of HIV-1 latency
Peripheral blood mononuclear cells were collected from unidentified, healthy donors following
protocols outlined in IRB #67637 (University of Utah Institutional Review Board approved).
Naïve CD4+ T cells were isolated using an immunomagnetic negative selection kit (EasySep ™
Human Naïve CD4+ T Cell Isolation Kit, STEMCELL™ Technologies, Cat. #19555). Following
isolation, cells were activated with human αCD3/αCD28-coated magnetic beads (1 bead/106
cells, Life Technologies, Cat. #11131D), αIL-4 (2 μg/106 cells, Peprotech, Cat. #500-p24), αIL-12
(4 μg/106 cells, Peprotech, Cat. #500-p154g) and tumor growth factor (TGF)-β1 (0.8 μg/106
cells, Peprotech, Cat. #100–21) for 3 days. Donor cells were subsequently infected at MOI 0.1
via spinoculation with HIVNluc2A (2,900 rpm for 2 hours at 37˚C). Infected cells were expanded
over 7 days. Viral replication was suppressed by incubating cells in nelfinavir (1 μM) for 16
hours at 37˚C, 5% CO2. Prior to assay, HIV
Nluc2A-infected CD4+ T cells were isolated (Dyna-
bead CD4-positive isolation kit, Life Technologies, Cat. #11551D) upon which cells were
resuspended in RPMI 1640 supplemented with 10% FBS, antibiotic-antimycotic solution,
recombinant human IL-2 (30 IU/mL, Dr. Maurice Gately, Hoffman-La Roche Inc. [60]), and
nelfinavir (1 μM). Cells were plated at a cell density of 50,000 cells/well in 96-well U-bottom
plates. Cells were incubated with the following conditions for 72 hours at 37˚C, 5% CO2 (in trip-
licate): PBS, αCD3/αCD28 beads (1 bead/106 cells), PIM6 (10 μg/mL), H37Rv lysate (100 μg/
mL), LAM (100 μg/mL), H37Ra (MOI 70:1) and M. smegmatis (MOI 70:1).
Flow cytometry
TLR-2 surface expression was determined using anti-human CD282-APC (and isotype control
(Biolegend, San Diego, CA)) Expression was measured in a BD FACSCanto II flow cytometer.
For analysis of TCM model, cells were stained with viability dye (Fixable Viability Dye
efluor450, affymetrix, eBioscience, San Diego, CA) and mouse anti-human CD4-APC anti-
body (cloneS3.5, Invitrogen) for 30 minutes at 4˚C followed by a fixation/permeabilization
step (FIX & PERM1 Cell Fixation & Cell Permeabilization Kit, ThermoFisher Scientific, Cat.
#GAS004). Cells were stained for intracellular p24 Gag by incubating cells with ICp24-FITC
antibody (KC57, Coulter) in BD Perm/Wash™ Buffer (BD Biosciences, Cat. #554723) for 30
minutes at 4˚C. Conditions were analyzed on BD FACS Scan. Data were analyzed by FlowJo
(TreeStar Inc., Ashland, OR).
Generation of pNL43-secNLuc2Anef
A PCR product containing the secNLuc gene flanked by 5’ NheI and 3’ BamHI restriction sites
was generated using PCR primers (5’-ccctgctagcgtcttcacactcgaagatttcgttgg
HIV-1 latency reversal by Mycobacterium tuberculosis
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gg and 5’-cgcgggatcccgccagaatgcgttcgcacagccg) and pNL1.3[secNLuc], a
plasmid containing the coding sequence for secreted NanoLuc1 luciferase (Promega, Cat.
#N1021). This PCR product and the plasmid pFIN-EF1-GFP-2A-HA-VPR-WPE were di-
gested with NheI and BamHI. The digested secNLuc PCR fragment and the10.6 kb fragment
from the EF1-GFP-2A-HA-VPR-WPE plasmid were ligated to generate pFIN-EF1-nLuc-
2A-HA-vpr-WRE. A PCR product containing the first 152 nucleotides of coding sequence of
the HIV-1 nef gene flanked by 5’ EcoRV and 3’ MluI was generated using PCR primers (5’-t
tttgcgatatcatgggtggcaagtggtcaaaaagtagtgtgatand 5’-ttagctgctgtaa
cgcgtcttgtgattgctccatgtttttctaggtc) and pNL4-3. The nef PCR product and
pFIN-EF1-secNluc-2A-HA-VPR-WRE plasmid were digested with EcoRV and MluI. The 10.8
kb fragment from the pFIN-EF1-secNluc-2A-HA-VPR-WRE plasmid and the EcoRV and
MluI digested nef PCR product were ligated to create the pFIN-EF1-secNluc-2A-nef-WRE
plasmid. An NcoI restriction site was introduced into pUC19 using site-directed mutagenesis
(QuickChange Lightning, Agilent Genomics) and primers (5’-ggtacccggggatcccatg
gagtcgacctgcaggand 5’-cctgcaggtcgactccatgggatccccgggtacc) to generate
the pUC19NcoI plasmid. The pUC19NcoI plasmid was digested with NcoI and SmaI. pNL4-3
was digested with NheI followed by incubation with the Klenow large fragment to fill in the
overhang created by NheI digestion. The resulting linearized plasmid was digested with NcoI
to create a 3318 bp fragment containing 1530 nucleotides of the 3’ coding sequence of HIV-1
env, the nef gene and the 3’ LTR. This fragment was ligated with the NcoI- and SmaI-digested
fragment of pUC19NcoI (2678 bp) to create pUC19HIVNcoINheI. A unique XbaI site within
the 5’ coding sequence of HIV-1 nef in pUC19HIVNcoINheI was generated using site-directed
mutagenesis (QuickChange Lightning, Agilent Genomics) and primers (5’-ccatccaatca
cactacttctagaccacttgccacccatct and 5’-agatgggtggcaagtggtctagaag
tagtgtgattggatgg) to create pUC19HIVNcoINheIaddXbaI. The pUC19HIVNcoIN-
heIaddXbaI plasmid was digested with XbaI and XhoI, a unique restriction site within the
HIV-1 nef gene. The pFIN-EF1-secNluc-2A-nef-WRE plasmid was digested with NheI and
XhoI to generate a 778 bp fragment containing secNluc, 2A and 106 bp of the 5’ coding
sequence of the HIV-1 nef gene. The 778 bp nLuc-2A-5’nef fragment was ligated to the 5911
bp XbaI XhoI fragment from pUC19HIVNcoINheIaddXbaI to replace 85 bp of coding se-
quence within the HIV-1 nef gene with secNluc-2A-5’nef. This reconstitutes the nef gene
through ligation of 5’ and 3’ termini at the native XbaI restriction site. The resulting plasmid,
named pUC19-secNluc2Anef, and pNL4-3 were digested with HpaI and NcoI. The 2611 bp
fragment from pUC19-secNluc2Anef and the 12961 bp fragment from pNL4-3 were ligated to
create pNL43-secNluc2Anef (S4 Fig).
Generation of HIVNLuc2A virus by calcium phosphate transfection
293FT cells were grown to approximately 70% confluency in 150 cm2 cell culture dishes. A
CaPO4-DNA suspension of pNL43-secNluc2Anef and pCMV-VSVg (approximately 25 μg
each) was prepared by diluting in ddH2O and subsequently mixing with CaCl2 (2.5 M) and 2X
HBS (pH 7.05). CaPO4-DNA suspension was added drop-wise to culture dishes followed by
the addition of chloroquine (100 mM). Cells were incubated for 16 hours and media was
replaced. Supernatant was recovered after 48 hours and sterile-filtered (0.45 μM). Viral titers
were determined using Sup-T1 cells.
Nanoluciferase assay
Ten microliter aliquots of the supernatant from TCM experiment wells were mixed with 0.1%
bovine serum albumin (BSA) in PBS. Nano-Glo1 Luciferase Assay Substrate (Promega) was
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diluted 1/50 in Nano-Glo1 Luciferase Assay Buffer (Promega). The mixture was incubated at
room temperature for 5 min and luminescence was quantified using a Biotek Synergy 2 micro-
plate reader.
Experimental and statistical analysis
Cell-line based assays (JLAT & JLAT-TLR2) were conducted in triplicate and mean values
were calculated across four and ten independent experiments, respectively. Significance was
determined using an unpaired, two-tailed Student’s t-test versus PBS. For inhibitor-based
assays, three independent experiments ran in triplicate were performed and mean values were
calculated. An unpaired, two-tailed Student’s t-test comparing test conditions in the absence
and presence of inhibitor was used to determine significance. The TCM model was run in trip-
licate across eight donors with the exception of PIM6 (n = 7) and H37Rv lysate (n = 5). Analy-
sis of flow cytometry data for the TCM model was conducted for the mean percent p24 positive
values for eight donors. Significance was determined using a paired, two-tailed Student’s t-test
versus PBS. For the NanoLuc1 luciferase assay, the mean relative luminescence units for each
donor was calculated and significance was determined using a paired, two-tailed Student’s t-
test versus PBS. All statistical analyses were performed using GraphPad Prism (GraphPad Soft-
ware, Inc., La Jolla, CA).
Ethics statement
PBMCs were collected from unidentified, healthy donors following protocols outlined in IRB
#67637 (University of Utah Institutional Review Board approved). All donors provided written
informed consent prior to entry to the study.
Supporting information
S1 Fig. TLR-2 overexpression in JLAT 10.6 cells. A) The lentiviral vector, pFIN-EF1-GFP-
2A-mCherry-WPRE, was engineered to express TLR-2 in place of GFP. B) Anti-human
CD282 (open black histogram) and isotype control (closed gray histogram) were used to deter-
mine surface expression of TLR-2.
(TIF)
S2 Fig. Reactivation of HIV by H37Ra, PIM6, and H37Rv lysate in a primary TCM model of
latency. Cultured TCM cells following 72-hour incubation with test conditions or co-stimula-
tion with αCD3/αCD28. (A) Levels of intracellular p24 Gag were measured by flow cytometry.
Each symbol corresponds to a different donor. Mean ± SD are indicated with the horizontal
lines.). (B) Relative luminescence was measured from supernatant of cultured TCM cells follow-
ing 72-hour incubation with conditions or co-stimulation with αCD3/αCD28. Each symbol
corresponds to a different donor. Mean ± SD are indicated with the horizontal lines. Signifi-
cance was determined using a 2-tailed, paired Student’s t-test versus PBS (p<0.05). Signifi-
cance of individual test conditions are as follows: αCD3/αCD28 (p0.01), PIM6 (p<0.05),
H37Ra (p0.01), and M. smegmatis (p0.01).
(TIF)
S3 Fig. H37Rv lysate induces p24 expression but suppresses luminescence in a primary
TCM model of latency. Cultured TCM cells following 72-hour incubation with test conditions
or co-stimulation with αCD3/αCD28. (A) Levels of intracellular p24 Gag were measured by
flow cytometry. The horizontal line within the box represents the media, the boundaries of the
box represent the 25th- and 75th-percentile, and the whiskers represent the maximum and
minimum values. Significance for intracellular p24 Gag was determined using a 2-tailed,
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paired Student’s t-test versus PBS (p<0.05). (B) Relative luminescence was measured from
supernatant of cultured TCM cells following 72-hour incubation with conditions or co-stim-
ulation with αCD3/αCD28. The horizontal line within the box represents the media, the
boundaries of the box represent the 25th- and 75th-percentile, and the whiskers represent the
maximum and minimum values. Significance was determined using a 2-tailed, paired Stu-
dent’s t-test versus PBS (p<0.05). (C) Supernatant from SupT1 cells infected with HIVNluc2A
(MOI 0.1) or supernatant from uninfected SupT1 cells (Mock) was incubated with H37Rv
lysate (100 μg/mL) for 72 hours at 37˚C after which point luminescence was measured. Signifi-
cance was determined using a one-tailed, unpaired Student’s t-test (p<0.05).
(TIF)
S4 Fig. Plasmid map of pNL43-secNluc2Anef.
(TIF)
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